Simranjit Singh is the CEO of Guardant Health, a precision oncology company that launched the first FDA-approved blood test for genomic testing across all solid cancers about 2 years ago. And just recently, Guardant Health AMEA was involved in a partnership with Adicon Holdings Limited, a leading independent clinical laboratory company based in China, to boost global research and diagnostic oncology efforts. Simranjit Singh joins Michelle Martin on Money and Me as he gives a breakdown of Guardant’s portfolio and efforts to effectively revolutionise the continuum of cancer care and improve clinical outcomes for cancer patients.

Market View: The AI Trade Faces a Reality Check as Oil Tops $100 , Oil Above $100 & what could move markets this week
14:51

Hyperbaric Oxygen Therapy: Medicine, Longevity Tool or Wellness Hype?
24:16

Money and Me : The Best Cards for Living Abroad to Earn Miles Without Losing Them to Fees
22:14